Biochem/physiol Actions
Reversible: no
Target IC50: 20 nM against Hedgehog (Hh) signaling in Shh-LIGHT2 assay; 50 nM in p2Ptch-/-cells; 500 nM in SmoA1-LIGHT cells
Product does not compete with ATP.
Primary TargetHh signaling in Shh-light2 assay
Cell permeable: yes
General description
A potent, cell-permeable analog of Cyclopamine (Cat. No. 239803) that specifically inhibits the Hedgehog (Hh) signaling with similar or lower toxicity (IC50 = 20 nM in Shh-LIGHT2 assay; 50 nM in p2Ptch-/-cells; 500 nM in SmoA1-LIGHT cells). Binds to SmoA1 and promotes its exit from the endoplasmic reticulum. Suppresses both the ShhNp-induced pathway activity and SmoA1-induced reporter activity. Shown to sensitize human glioma cells to TRAIL-induced apoptosis. Also available as a 1 mM solution in DMSO (Cat. No. 239807).
A cell-permeable potent analog of Cyclopamine (Cat. No. 239803) that specifically inhibits Hedgehog (Hh) signaling with similar or lower toxicity (IC50 = 20 nM in Shh-LIGHT2 assay; 50 nM in p2Ptch-/-cells; 500 nM in SmoA1-LIGHT cells). Binds to SmoA1 and promotes its exit from the endoplasmic reticulum. Suppresses both ShhNp-induced pathway activity and SmoA1-induced reporter activity. Reported to cause regression of murine tumor allografts in vivo and induce rapid cell death in human medulloblastoma. Shown to sensitize human glioma cells to TRAIL-induced apoptosis.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Siegelin, M.D. et al. 2009. Neurobiol. Dis.34, 259.Watkins, D.N., et al. 2003. Nature422, 313.Berman, D.M., et al. 2002. Science297, 1559.Chen, J.K., et al. 2002. Proc. Natl. Acad. Sci. USA99, 14071.Chen, J.K., et al. 2002. Genes Dev.16, 2743.Frank-Kamenetsky, M., et al. 2002. J. Biol.1, 10.Taipale, J., et al. 2000. Nature406, 1005.
Packaging
100, 500 µg in Glass bottle
Packaged under inert gas
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 weeks at -20°C.
Warning
Toxicity: Harmful (C)
This product has met the following criteria to qualify for the following awards: